Comparable stake leader
Ever Regal Group Ltd
SEC ownership of BeyondSpring Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001677940.
Disclosed value leader
Ever Regal Group Ltd
Comparable rows
26/33
Latest evidence
01 Jul 2026
- Public ticker
- BYSI on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ever Regal Group Ltd
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 33
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Ever Regal Group Ltd
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001677940
- Issuer location
- Florham Park, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BeyondSpring Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ever Regal Group Ltd
Disclosed value leader
Ever Regal Group Ltd
Comparable rows
26/33
Latest evidence
01 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 15%
7 rows are not safely comparable across share classes.
13D/G row: Ever Regal Group Ltd
Showing 1-8 of 33 holder rows.
Quick read
Ever Regal Group Ltd leads the comparable SEC ownership view at 15%.
26 of 33 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ever Regal Group Ltd's linked filing trail.
Comparable ownership
Top 5
Ever Regal Group Ltd
15%
Lan Huang
13%
Decheng Capital Management III (C...
9.2%
Decheng Capital China Life Scienc...
9.8%
Decheng Capital LLC
9.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 33 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ever Regal Group Ltd |
13D/G
Lan Huang
|
15%
|
$9,375,156
6,048,488 shares
|
$0 | 31 Dec 2024 |
| Lan Huang |
13D/G
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
13%
|
$8,787,117
5,293,444 shares
|
-$820,807 | 30 Jun 2026 |
| Decheng Capital Management III (Cayman), LLC |
13D/G
Xiangmin Cui
|
9.2%
|
$6,043,116
3,800,702 shares
|
-$1,161,939 | 31 Dec 2025 |
| Decheng Capital China Life Sciences USD Fund III, L.P. |
3/4/5
10%+ Owner
|
9.8%
|
$7,039,159
4,028,036 shares
|
-$498,272 | 16 Oct 2025 |
| Decheng Capital LLC |
13F
Company
|
9.3%
|
$6,651,229
3,800,702 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
1.6%
|
$1,177,602
672,915 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.5%
|
$1,096,300
626,457 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.9%
|
$643,910
367,740 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$511,560.
Buys
$0
Insiders: 0
Sells
$511,560
Insiders: 1
Net
-$511,560
Shares: -299,003
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 299,003
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 299,003 | $0 | $511,560 | -$511,560 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to BeyondSpring Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Decheng Capital China Life Sciences USD Fund III, L.P.
Net 12M change
-$498,272
Latest report
01 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | 10%+ Owner | $7,039,159 | -$498,272 | -6.6% | Mixed | 16 Oct 2025 |
| Lan Huang | Chief Executive Officer, Director, 10%+ Owner | $829,560 | Mixed | 01 Apr 2026 | ||
| Min Qiu | Chief Executive Officer | $4,096 | Mixed | 01 Jul 2026 | ||
| Brendan Delaney | Director | Mixed | 01 Apr 2026 | |||
| Patrick Fabbio | Director | Mixed | 01 Apr 2026 | |||
| Jiangwen Majeti | Director | Mixed | 01 Jul 2026 | |||
| Na (nl) Li | Chief Financial Officer | Mixed | 01 Jul 2026 | |||
| Yingjuan June Lu | Chief Scientific Officer | Mixed | 01 Apr 2026 | |||
| Sihai Xu | Director | Mixed | 01 Apr 2026 | |||
| Matthew Kirkby | Director | Mixed | 01 Apr 2026 |
Recent insider transactions for BeyondSpring Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jiangwen Majeti | BYSI | Stock Options (right to buy) | Award | 100,000 | 100,000 | 01 Jul 2026 | Direct | |||
| Min Qiu | BYSI | Stock Options (right to buy) | Award | 100,000 | 100,000 | 01 Jul 2026 | Direct | |||
| Matthew Kirkby | BYSI | Stock Options (right to buy) | Award | 23,902 | 23,902 | 01 Apr 2026 | Direct | |||
| Patrick Fabbio | BYSI | Stock Options (right to buy) | Award | 22,165 | 22,165 | 01 Apr 2026 | Direct | |||
| Brendan Delaney | BYSI | Stock Options (right to buy) | Award | 20,427 | 20,427 | 01 Apr 2026 | Direct | |||
| Jiangwen Majeti | BYSI | Stock Options (right to buy) | Award | 21,730 | 21,730 | 01 Apr 2026 | Direct | |||
| Yingjuan June Lu | BYSI | Stock Options (right to buy) | Award | 17,840 | 17,840 | 01 Apr 2026 | Direct | |||
| Lan Huang | BYSI | Stock Options (right to buy) | Award | 11,514 | 11,514 | 01 Apr 2026 | Direct | |||
| Sihai Xu | BYSI | Stock Options (right to buy) | Award | 18,689 | 18,689 | 01 Apr 2026 | Direct | |||
| Lan Huang | BYSI | Ordinary Shares | Gift | -100% | -260,582 | 0 | 20 Mar 2026 | By Lan Huang 2022 Grantor Retained Annuity Trust | ||
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -2.91% | $80,103 | $1.76 | -45,513 | 1,518,893 | 17 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -5.2% | $147,573 | $1.72 | -85,798 | 1,564,406 | 16 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -1.08% | $29,634 | $1.65 | -17,960 | 1,650,204 | 15 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -1.68% | $47,017 | $1.65 | -28,495 | 1,668,164 | 14 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -5.95% | $182,514 | $1.70 | -107,361 | 1,696,659 | 13 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -0.13% | $4,230 | $1.77 | -2,390 | 1,804,020 | 10 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -0.22% | $7,202 | $1.81 | -3,979 | 1,806,410 | 09 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | Ordinary Shares | Sale | -0.41% | $13,287 | $1.77 | -7,507 | 1,810,389 | 08 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
* marks a reported price that did not pass the local price check.